Beone Medicines Polandsp. z o.o.
Research and experimental development in natural sciences and engineering
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2022-05-25
Share capital
5,000.00 PLN
Average employment (people)
41 (2025)
Registered address
Rondo Organizacji Narodów Zjednoczonych 1/24 piętro, 00-124 Warszawa, Poland
Financials
Revenue history (in k)
Financial insight
- Estonian CIT: Equity includes non-zero Art. 28d line items – the company is taxed under the lump-sum regime on corporate income.
From the notes
| Current income tax (CIT due) | $216,289 | |
| Profit allocation | No decision | |
| Foreign sales | 100% of revenue ($8,937,411) | |
| Management board pay | $283,612 | |
| Deferred tax assets | $694,411 | |
| Deferred tax liability | $440,286 |
Filing timeliness
4 of 4 financial statements were filed late (the longest delay 264 days for 2022).
- 202502/10/2026
- 202431/07/2025
- 202322/07/2024
- 202204/04/2024
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Industry · Research and experimental development in natural sciences and engineering22 / 277
Top 7.9%
Results vs industry
Revenue
This companyUSD 9.08mMedianUSD 152.85kAverageUSD 4.86m
Net profit
This companyUSD 478.12kMedianUSD -228.23AverageUSD 317.06k
Operating costs
This companyUSD 8.38mMedianUSD 187.91kAverageUSD 4.67m
Assets
This companyUSD 2.57mMedianUSD 278.35kAverageUSD 8.47m
Industry
Authorized Representatives
Pierre Bernard Malpot – Management Board Member
Marek Dariusz Smela – Management Board Member
Manner of representation
Each member of the management board has the right to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Beone Medicines i Gmbh | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2022-07-04.
54 1280 0003 0000 0031 8976 8031
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| ArdigenS.A. | $12,513,309.89 | ardigen.com | ||
| Centrum Naukowo-Badawcze Ochrony Przeciwpożarowej Im. Józefa Tuliszkowskiego - Państwowy Instytut BadawczyResearch institute | $11,221,681.24 | cnbop.pl | ||
| Centrum Techniki OkrętowejS.A. | $10,041,376.36 | cto.gda.pl | ||
| Telesystem GroupS.A. | $9,093,586.25 | mikroel.tech | ||
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Sieć Badawcza Łukasiewicz – Instytut Sztucznej Inteligencji I CyberbezpieczeństwaResearch institute | $6,514,456.26 | ai.lukasiewicz.gov.pl | ||
| SR Roboticssp. z o.o. | $4,456,035.13 | srrobotics.pl | ||
| XtplS.A. | $3,872,928.18 | xtpl.com | ||
| Agencja Rynku EnergiiS.A. | $2,676,821.15 | are.waw.pl | ||
| Fluence Technologysp. z o.o. | $2,486,673.06 | fluence.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-07-21 | Address change (Ul. Tadeusza Czackiego 15/17, 00-043, Warszawa → Rondo Organizacji Narodów Zjednoczonych 1/24 Piętro, 00-124, Warszawa) | |
| 2025-08-25 | Name change (Beigene Poland → Beone Medicines Poland) | |
| 2025-08-25 | Switch to PKD 2025 (1 PKD 2007 code → 1 PKD 2025 code) | |
| 2025-05-30 | Address change (Rondo Ignacego Daszyńskiego 2b, 00-843, Warszawa → Ul. Tadeusza Czackiego 15/17, 00-043, Warszawa) | |
| 2023-07-07 | Address change (Plac Marsz. Józefa Piłsudskiego 1, 00-078, Warszawa → Rondo Ignacego Daszyńskiego 2b, 00-843, Warszawa) |
FAQ
The main business activity of Beone Medicines Poland focuses on research and experimental development in natural sciences and engineering.
The company was registered in the Polish National Court Register (KRS) on May 25, 2022.
The headquarters is located at: Rondo Organizacji Narodów Zjednoczonych 1, 00-124 Warszawa.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD 9,081,655 in 2025, which is an increase of 49.6% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of USD 478,123, meaning the company increased its profit by 299.9%.
The largest operating cost category falls under employee remuneration. This category amounted to USD 4,694,269 in 2025, representing 56% of all operating expenses.
Last updated: 2026-10-07